HDL cholesterol and cardiovascular outcomes: what is the evidence? (Q38082718)

28 August 2017

title

HDL cholesterol and cardiovascular outcomes: what is the evidence? (English)

1 reference

28 August 2017

Melvyn Rubenfire

1 reference

28 August 2017

Robert D Brook

series ordinal

1 reference

28 August 2017

language of work or name

1 reference

1 April 2013

1 reference

Current cardiology reports

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

349

1 reference

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

High-density lipoprotein as a therapeutic target: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Clinical practice. Low HDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Hea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Genetic causes of high and low serum HDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

High-density lipoprotein particle size and concentration and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

HDL as a biomarker, potential therapeutic target, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Approach to the patient with extremely low HDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Apolipoprotein A-I(Milano): current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Effects of lifestyle interventions on high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Antiatherothrombotic effects of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Combined statin and niacin therapy remodels the high-density lipoprotein proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0349-3

Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study.

21 January 2018

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

High-density lipoprotein cholesterol as the Holy Grail

1 reference

12 December 2020

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

12 December 2020

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals

1 reference

12 December 2020

Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

10.1007/S11886-013-0349-3

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1012317751

0 references

1 reference